Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma

References

• McLaughlin JK, Lipworth L. Epidemiologic aspects of renal cell cancer. Semin Oncol. 2000;27(2):115–123.
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Stadler WM. Kidney cancer. Lancet. 1998;352(9141):1691–1696.
   Web of Science ®Google Scholar
• Godley PA, Taylor M. Renal cell carcinoma. Curr Opin Oncol. 2001;13(3):199–203.
   PubMed Web of Science ®Google Scholar
• Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166(5):1611–1623.
   PubMed Web of Science ®Google Scholar
• Campbell SC, Flanigan RC, Clark JI. Nephrectomy in metastatic renal cell carcinoma. Curr Treat Options Oncol. 2003;4(5):363–372.
   PubMedGoogle Scholar
• Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80(5):987–989.
   Google Scholar
• Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol. 2000;27(2):177–186.
   PubMed Web of Science ®Google Scholar
• Rey PM, Villavicencio H. Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience. Oncology. 2008;74(3–4):245–246.
   PubMed Web of Science ®Google Scholar
• Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005;1:CD001425.
   Web of Science ®Google Scholar
• Yang JC, Rosenberg SA. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer JSci Am. 1997;3 Suppl 1:S79–S84.
   Google Scholar
• Gitlitz BJ, Belldegrun A, Figlin RA. Immunotherapy and gene therapy. Semin Urol Oncol. 1996;14(4):237–243.
   Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–954.
   PubMed Web of Science ®Google Scholar
• Alavi A, Hood JD, Frausto R, et al. Role of Raf in vascular protection from distinct apoptotic stimuli. Science. 2003;301(5629):94–96.
   PubMed Web of Science ®Google Scholar
• Hood JD, Bednarski M, Frausto R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002;296(5577):2404–2407.
   PubMed Web of Science ®Google Scholar
• Thomas GV Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006;12(1):122–127.
   PubMed Web of Science ®Google Scholar
• Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22(24):4991–5004.
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–134.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–124.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J Clin Oncol. 2010;28(6):1061–1068.
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–2781.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled Phase III trial. Lancet. 2008;372(9637):449–456.
   PubMed Web of Science ®Google Scholar
• Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28(13):2144–2150.
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28(13):2137–2143.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5(10):835–844.
   PubMed Web of Science ®Google Scholar
• Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43–9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59(5):561–574.
   PubMed Web of Science ®Google Scholar
• Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43–9006. J Clin Oncol. 2006;24(9):1363–1369.
   PubMed Web of Science ®Google Scholar
• Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 2009;69(2):223–240.
   PubMed Web of Science ®Google Scholar
• Lathia C, Lettieri J, Cihon F, et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol. 2006;57(5):685–692.
   PubMed Web of Science ®Google Scholar
• Furuse J, Ishii H, Nakachi K, et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci. 2008;99(1):159–165.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(26):4293–4300.
   PubMed Web of Science ®Google Scholar
• Porta C, Bracarda S. Presente e futuro di sorafenib in oncologia - Ed Accademia Nazionale di Medicina. Genoa: Forum Service; 2011.
   Google Scholar
• Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43–9006, in patients with advanced, refractory solid tumors. Clin Cancer Res. 2005;11(15):5472–5480.
   PubMed Web of Science ®Google Scholar
• Strumberg D, Schultheis B, Adamietz IA, et al. Phase I dose escalation study of telatinib (BAY 57–9352) in patients with advanced solid tumors. Br J Cancer. 2008;99(10):1579–1585.
   PubMed Web of Science ®Google Scholar
• Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 2009;27(11):1800–1805.
   PubMed Web of Science ®Google Scholar
• Strumberg D, Voliotis D, Moeller JG, et al. Results of Phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43–9006 in patients with solid tumors. Int J Clin Pharmacol Ther. 2002;40(12):580–581.
   PubMedGoogle Scholar
• Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43–9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumors. Br J Cancer. 2005;92(10):1855–1861.
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(16):2505–2512.
   PubMed Web of Science ®Google Scholar
• Maroto-Rey P, Bellmunt J, Trigo JM et al. First-line phase II trial of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma unsuitable for cytokine treatment. ASCO Annual Meeting Proceedings. J Clin Oncol, 2007; I(25)Supp18:15640.
   Google Scholar
• Szczylik C, Demkow T, Staehler M, et al. Randomised phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 2007;25(18):5025.
   Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27(20):3312–3318.
   PubMed Web of Science ®Google Scholar
• Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008;26(28):4572–4578.
   PubMed Web of Science ®Google Scholar
• Lamuraglia M, Escudier B, Chami L, et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer. 2006;42(15):2472–2479.
   PubMed Web of Science ®Google Scholar
• Stadler WM, Figlin RA, McDermott DF, et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010;116(5):1272–1280.
   PubMed Web of Science ®Google Scholar
• J Beck, G Procopio, U Keilholz, et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol. February 15, 2011. [Epub ahead of print].
   Google Scholar
• Nexavar FDA product information. http://berlex.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf. Accessed March 1, 2011.
   Google Scholar
• Hutson TE, Bellmunt J, Porta C, et al. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from Phase III TARGET. Eur J Cancer. 2010;46(13):2432–2440.
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Appleman LJ, Shapiro GI, et al. A Phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. June 3, 2010. [Epub ahead of print].
   Web of Science ®Google Scholar
• Parsa VK, Heilbrun L, Smith D, et al. Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function [abstract 365]. Proceedings of the 2008 Genitourinary Cancers Symposium.
   Google Scholar
• Rathmell WK, Chen S. VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Rev Anticancer Ther. 2008;8(1):63–73.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008;26(1):127–131.
   PubMed Web of Science ®Google Scholar
• Golshayan AR, George S, Heng DY, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol. 2009;27(2):235–241.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Eisen T, Szczylik C, et al. A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. BJU Int. 2010 [Epub ahead of print].
   Web of Science ®Google Scholar
• Aapro MS, Kohne CH, Cohen HJ, Extermann M. Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist. 2005;10(3):198–204.
   PubMed Web of Science ®Google Scholar
• Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25(14):1824–1831.
   PubMed Web of Science ®Google Scholar
• Eisen T, Oudard S, Szczylik C, et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst. 2008;100(20):1454–1463.
   PubMed Web of Science ®Google Scholar
• Bukowski RM. Renal cell carcinoma: a model system for novel drug development? Clin Genitourin Cancer. 2008;6(1):7–8.
   Web of Science ®Google Scholar
• Porta C, Paglino C, Imarisio I, Ferraris E. Sorafenib tosylate in advanced kidney cancer: past, present and future. Anticancer Drugs. 2009;20(6):409–415.
   Web of Science ®Google Scholar
• Bukowski R, Cella D, Gondek K, Escudier B. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol. 2007;30(3):220–227.
   Web of Science ®Google Scholar
• Beck J, Procopio G, Negrier S, et al. Final analysis of a large open-label, noncomparative study of sorafenib in European patients with advanced RCC (EU-ARCCS) [poster]. Presented at the 34th ESMO Annual Congress; September 20–24, 2009. Berlin, Germany.
   Google Scholar
• Flaherty KT, Brose MS. Sorafenib-related hand-foot skin reaction improves, not worsens, with continued treatment. Clin Cancer Res. 2009;15(24):7749.
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008;13(9):1001–1011.
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol. 2008;19(11):1955–1961.
   PubMed Web of Science ®Google Scholar
• Nexavar EMA product information: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000690/WC500027704.pdf. Accessed March 1, 2011.
   Google Scholar
• Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 2009;48(7):964–970.
   PubMed Web of Science ®Google Scholar
• Halbert RJ, Figlin RA, Atkins MB, et al. Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer. 2006;107(10):2375–2383.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN guidelines for renal cell carcinoma. V 2.2011 http://www.nccn.org/professionals/physi- cian_gls/f_guidelines.asp. Accessed March 1, 2011.
   Google Scholar
• Bellmunt J, Fishman M, Eisen T, Quinn D. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert Rev Anticancer Ther. 2010;10(6):825–835.
   PubMed Web of Science ®Google Scholar
• Escudier B, Szczylik C, Hutson TE, et al. Randomized Phase II trial of first-line treatment with sorafenib versus interferon a-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2001;27(8):1280–1289.
   Google Scholar
• Ryan CW, Goldman BH, Lara PN Jr, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a Phase II study of the Southwest Oncology Group. J Clin Oncol. 2007;25(22):3296–3301.
   PubMed Web of Science ®Google Scholar
• Jonasch E, Corn P, Pagliaro LC, et al. Upfront, randomized, Phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer. 2010;116(1):57–65.
   Web of Science ®Google Scholar
• Garcia JA, Hutson TE, Elson P, et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer. 2010;116(23):5383–5390.
   PubMed Web of Science ®Google Scholar
• Kontovinis L, Laschos K, Karadimou A, et al. Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study. Med Oncol. January 30, 2011. [Epub ahead of print].
   Web of Science ®Google Scholar
• Tamaskar I, Garcia JA, Elson P, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol. 2008;179(1):81–86; discussion 86.
   Web of Science ®Google Scholar
• Beck J, Procopio G, Bajetta E, et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol. February 15, 2011. [Epub ahead of print].
   Google Scholar
• Sablin MP, Negrier S, Ravaud A, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol. 2009;182(1):29–34; discussion 34.
   PubMed Web of Science ®Google Scholar
• Dudek AZ, Zolnierek J, Dham A, et al. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer. 2009;115(1):61–67.
   PubMed Web of Science ®Google Scholar
• De Reijke TM, Bellmunt J, van Poppel H, et al. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer. 2009;45(5):765–773.
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Imarisio I. Sequencing tyrosine kinase inhibitors or immediately switching to mTOR inhibitors in advanced kidney cancer: a critical review. European J Clin Med Oncol. December 21, 2010. [Epub ahead of print].
   Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116(18):4256–4265.
   PubMed Web of Science ®Google Scholar
• Vickers MM, Choueiri TK, Rogers M, et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology. 2010;76(2): 430–434.
   PubMed Web of Science ®Google Scholar